Tags Archive Navigation
icon
-
Media ReleaseNovartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
-
Media ReleaseEuropean Medicines Agency (EMA) approves safety label update for Novartis Beovu®
-
Media ReleaseNovartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
-
Media ReleaseNovartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
-
Media ReleaseNovartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumumab) Sensoready® autoinjector pen
-
Media ReleaseNovartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
-
Media ReleaseNovartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
-
Media ReleaseNovartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis
-
Media ReleaseKesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS
-
Media ReleaseWichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt
-
Media ReleaseNovartis: moteurs clés de la croissance et lancements poursuivent leur essor au 1er trimestre, maintenant la confiance dans la croissance. Confirmation des prévisions pour le Groupe pour 2021
-
Media ReleaseNovartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- › Next page